All News
#immune #reset may be ‘asking the earth’ and we may need to consider #immune #dimming
➡️esp if multi drug failure already
By Hector Chinoy #WIN #IIM June5
Excellent #CAR-T review
should re think of
Total immune reset in many #SARD PTS is unlikely
EULAR2026 @RheumNow https://t.co/eqKzxzqa0z
Links:
Janet Pope Janetbirdope ( View Tweet)
Can we finally personalize MTX dosing in #RA? liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (n=59): MTX-PG3 levels ↑ with dose and age, ↓ with higher disease activity and concomitant biologics. Route (oral vs SC) didn't matter. @RheumNow #EULAR2026 POS0251
Jiha Lee JihaRheum ( View Tweet)
#proof of #concept in #Sjogren’s #dis
#lanalumab Treatment reduced in #SjD
✅reduced B cells in #salivary #glands
—nearly complete depletion in serum
✅reduced B cell activation
✅improved #inflammation of
#parotid & #submandibular glands
@RheumNow #EULAR2026
#OP0163
#POS0284
Janet Pope Janetbirdope ( View Tweet)
Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period
MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup
OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6
Links:
sheila RHEUMarampa ( View Tweet)
#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC
Mrinalini Dey DrMiniDey ( View Tweet)
Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated.
Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067
Bella Mehta bella_mehta ( View Tweet)
Sarcoidosis increases the risk of MGUS and multiple myeloma. Propensity matched Data from a large global collaborative network study with 40k pts.
POS0231 #EULAR2026 @RheumNow https://t.co/mygYCjigFV
Bella Mehta bella_mehta ( View Tweet)
#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB
TheDaoIndex KDAO2011 ( View Tweet)
Understanding how Bispecific T cell engagers work: remarkable mode of action!
Let’s hope it works as well as in oncology!
#teclistamab in #SSc
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/waSCXKA79Y
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy
Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Many drugs in the pipeline for #Systemic_Sclerosis
In particular, stay tuned for:
🔺Nerandomilast (PDE4i) in ILD
🔺CAR T cells (obviously): big RCT trials planned
🔺Bispecific T cell engagers: Teclistamab
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/I7HQtfwuW0
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#OP0350 UK Biobank analysis found widespread white matter microstructural abnormalities on diffusion MRI in RA, esp in fronto-subcortical & transcallosal pathways, despite no cortical volume/thickness differences on T1 MRI. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Live vaccinations in infants antenatally exposed to bDMARDs
⬇️⬇️
#WIN session @lauraandreoli80
#EULAR2026 @RheumNow https://t.co/84MCwb2fbT
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Starting the “Imaging innovation in RA” session with #OP0343: Singapore investigators developed an AI-based thermography model to detect RA wrist inflammation using thermal hand images, achieving an AUC of 0.87 against ultrasound power doppler as reference. #EULAR2026 @RheumNow https://t.co/2v39E6VOWB
Mrinalini Dey DrMiniDey ( View Tweet)
This study describes the SIJ differences in axSpA vs. non-axSpA pts with CBP
axSpA: BME w/ widespread distribution & inflamm⬇️ over time
non-axSpA: BME rare or limited only to ventral & middle superior sacrum
Findings may improve MRI ID of axSpa
AbsPOS0193 @RheumNow #EULAR2026 https://t.co/7eiHQOOIWs
sheila RHEUMarampa ( View Tweet)
#OP0344 RADAR, AI-automated scoring of RA radiographic damage, was applied to 20yr ESPOIR imaging data. Strong performance vs expert readers, w binary classification accuracy up to 0.95 & ICC 0.86. Supports AI-assisted long-term structural assessment in RA. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
CAR-T Cell Therapies in Refractory RMD Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed CAR-T cell therapy may https://t.co/lXX5RjEw6a
Dr. John Cush RheumNow ( View Tweet)
JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal
Few topics in rheumatology have reshaped prescribing behavior as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. Even https://t.co/wfQZn1hO3N
Dr. John Cush RheumNow ( View Tweet)
